Results 241 to 250 of about 9,905,323 (311)
Development of a nalmefene formulation suitable for a community‐use auto‐injector
Aim Time to onset of reversal is critical when treating opioid‐induced respiratory depression and hypoxia. This study aimed to develop a formulation of the opioid antagonist nalmefene with an increased absorption rate and reduced time to onset of reversal following intramuscular administration. Methods Several absorption enhancers were screened in rats,
Alessandra Cipriano +6 more
wiley +1 more source
Chronic pain represents a complex debilitating condition that extends beyond the protective function of physiological pain, often persisting as an independent disease entity. Chronic primary and secondary pain syndromes reflect a multifaceted continuum involving nociceptive, neuropathic and nociplastic mechanisms.
Stefania Nobili +6 more
wiley +1 more source
Aims The glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) semaglutide and liraglutide are approved for chronic weight management. Both drugs also have favourable effects on the risk of developing diabetes and cardiovascular disease (CVD) compared with placebo, but their comparative effectiveness for these outcomes is unclear.
Ethan J. Cannon +7 more
wiley +1 more source
Regulatory harmonization: Evolution, globalization and future directions
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm +2 more
wiley +1 more source
Aims This work aimed to evaluate the efficacy and safety of cannabinoids for the treatment of MS‐related spasticity. Methods Systematic searches were conducted in PubMed, EMBASE, and LILACS on 2 December 2025. Randomized controlled trials evaluating natural or synthetic cannabinoids for MS‐related spasticity were included.
Letícia Hamm‐Buiar +3 more
wiley +1 more source
Aims Golcadomide is a potential first‐in‐class oral CELMoD™ agent for the treatment of lymphoma. This study aims to develop model‐informed drug development (MIDD) approaches to support optimal dose selection of golcadomide in combination with immunotherapy rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R‐CHOP) in alignment with ...
Xirong Zheng +7 more
wiley +1 more source
Counting your chickens before they hatch: improvements in an untreated chronic pain population, beyond regression to the mean and the placebo effect. [PDF]
Sean M +6 more
europepmc +1 more source
Aims This study aimed to evaluate the acute effects of cannabidiol plus tetrahydrocannabinol (CBD+THC) and tetrahydrocannabinol (THC) oils on cardiovascular haemodynamics, respiratory muscle activity and peripheral tissue perfusion in healthy adults. Methods In this randomized, double‐blind, crossover trial, participants received orally administered ...
Edna Karla Ferreira Laurentino +9 more
wiley +1 more source
[Placebo effect in the treatment with antidepressants : Implications for the scientific evaluation and clinical use of pharmaceutical treatments of depression]. [PDF]
Rief W, Kube T.
europepmc +1 more source

